

*[Handwritten signature]*



PATENTS  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Is the Application of:

**HEMBROUGH ET AL.**

Serial No. 10/608,886

Filed: **June 26, 2003**

For: **COMPOSITIONS AND METHODS  
COMPRISING PROTEINASE ACTIVATED  
RECEPTOR ANTAGONISTS**

)  
)  
) Art Unit: 1654  
)  
) Examiner: **Thomas S. Heard**  
)  
) Attorney No: **05213-3041 (13663-105099)**  
)  
)  
)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants cite the information on the attached Form PTO/SB/08A, "Information Disclosure Statement by Applicant," pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed with the exception that copies of U. S. patents are not being provided pursuant to the wavier of 37 C.F.R. §1.98 for patent applications filed after June 30, 2003. Applicants have enclosed copies of all other references.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a Final Office Action or a Notice of Allowance. Form PTO-2038 is enclosed to

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 31st day of May, 2007.

06/04/2007 TNGUYEN2 00000127 10608886

01 FC:1806


180.00 <sup>00</sup>

*[Signature: S. Lynn Freeman-Rees]*  
S. Lynn Freeman-Rees - Patent Specialist

cover the fee of \$180 as required by 37 C.F.R. § 1.17(p). The Commissioner is authorized to charge any additional fees, or to credit any overpayment, to Deposit Account No. 11-0980.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

  
Shirley E. Brosmore  
Reg. No. 56,167

King & Spalding LLP  
34th Floor, 1180 Peachtree Street, N.E.  
Atlanta, GA 30309-3521  
404.572.4600  
Our Docket: 05213-3041 (13663-105099)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

## Complete if Known

Application No.

10/608,886

Filing Date

06/26/2003

First Named Inventor

Hembrough et al.

Group Art Unit

1654

Examiner Name

Thomas S. Heard

Attorney Docket Number

05213-3041 (13663-105099)

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	1	GR	2000100283		Alexopoulos Konstantinos et al.	05/09/2002		

Examiner  
SignatureDate  
Considered

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known		
				Application No.	10/608,886	
				Filing Date	06/26/2003	
				First Named Inventor	Hembrough et al.	
				Group Art Unit	1654	
				Examiner Name	Thomas S. Heard	
Sheet	2	of	2	Attorney Docket Number		05213-3041 (13663-105099)
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T <sup>6</sup>
	2	Author: ELLIOTT et al. Title: Photoactivatable Peptides Based on BMS-197525: A Potent Antagonist of the Human Thrombin Receptor (PAR-1) Publ: Bioorganic & Medicinal Chemistry Letters Vol/Iss: 9 Pages: 179-284 Date: 01/01/1999				
	3	Author: KAWAGOE et al. Title: Effect of Protease-Activated Receptor-2 Deficiency on Allergic Dermatitis in the Mouse Ear Publ: Japanese Journal of Pharmacology Vol/Iss: 88 Pages: 77-84 Date: 01/01/2002				
	4	Author: MA et al. Title: Thrombin-Induced Platelet Endostatin Release is Blocked by a Proteinase Activated Receptor-4 (PAR4) Antagonist Publ: British Journal of Pharmacology Vol/Iss: 134 (4) Pages: 701-704 Date: 01/01/2001				
	5	Author: MARYANOFF et al. Title: Protease-Activated Receptor-2 (PAR-2): Structure-Function Study of Receptor Activation by Diverse Peptides Related to Tethered-Ligand Epitopes Publ: Archives of Biochemistry and Biophysics Vol/Iss: 386 (2) Pages: 195-204 Date: 02/15/2001				
	6	Author: ROY et al. Title: Dual Endothelium-Dependent Vascular Activities of Proteinase-Activated Receptor -2-Activated Peptides: Evidence for Receptor Heterogeneity Publ: British Journal of Pharmacology Vol/Iss: 123 Pages: 1434-1440 Date: 01/01/1998				
	7	Author: SHPACOVITCH et al. Title: Agonists of Proteinase-Activated Receptor 2 Induce Cytokine Release and Activation of Nuclear Transcription Factor κB in Human Dermal Microvascular Endothelial Cells Publ: The Journal of Investigative Dermatology Vol/Iss: 118 (2) Pages: 380-385 Date: 02/02/2002				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup>Applicant is to place a check mark here if English language translation is attached.